Scott B. Ullem - 07 May 2022 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role: CVP, Chief Financial Officer
Signature: Linda J. Park, Attorney-in-Fact
Issuer symbol: EW
Transactions as of: 07 May 2022
Transactions value $: -$954,940
Form type: 4
Filing time: 10 May 2022, 20:53:24 UTC
Previous filing: 05 May 2022
Next filing: 17 May 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EW	Common Stock	Tax liability	-$77,601	-772	-2.98%	$100.52	25,111	07 May 2022	Direct
transaction	EW	Common Stock	Options Exercise	$0	+14,831	+59.06%	$0	39,942	08 May 2022	Direct	F1
transaction	EW	Common Stock	Tax liability	-$877,338	-8,728	-21.85%	$100.52	31,214	08 May 2022	Direct
holding	EW	Common Stock						244,739	07 May 2022	By Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EW	Performance Rights	Options Exercise	$0	-14,831	-100%	$0^*	0	08 May 2022	Common Stock	14,831		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4.

Content

On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.